<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002076</url>
  </required_header>
  <id_info>
    <org_study_id>012J</org_study_id>
    <secondary_id>056-162</secondary_id>
    <nct_id>NCT00002076</nct_id>
  </id_info>
  <brief_title>Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis</brief_title>
  <official_title>Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal&#xD;
      meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiviral therapy such as zidovudine.&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Written informed consent must be obtained for each patient, either from the patient himself&#xD;
        or from the patient's legal guardian.&#xD;
&#xD;
          -  No prior systemic antifungal therapy for cryptococcosis.&#xD;
&#xD;
          -  Success of prior therapy must have been documented by negative cerebrospinal fluid&#xD;
             (CSF) culture at the end of therapy. Following prior therapy, such patients may not&#xD;
             have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into&#xD;
             study.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiviral therapy such as zidovudine.&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of acute or chronic meningitis based upon any etiology other than&#xD;
             cryptococcosis.&#xD;
&#xD;
          -  History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.&#xD;
&#xD;
          -  Moderate or severe liver disease defined by specified lab values.&#xD;
&#xD;
          -  Patients who are unable to take oral medication.&#xD;
&#xD;
          -  Unlikely to survive more than 2 weeks.&#xD;
&#xD;
          -  Renal impairment.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Coumarin-type anticoagulants.&#xD;
&#xD;
          -  Oral hypoglycemics.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Immunostimulants.&#xD;
&#xD;
          -  Investigational drugs or approved (licensed) drugs for investigational indications&#xD;
             other than aerosolized pentamidine.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Greater than 1 mg/kg/wk amphotericin B.&#xD;
&#xD;
          -  Any exceptions to these prohibitions of concomitant medications must be approved by&#xD;
             Pfizer Central Research.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Evidence of acute or chronic meningitis based upon any etiology other than&#xD;
             cryptococcosis.&#xD;
&#xD;
          -  History of allergy to or intolerance of imidazoles or azoles.&#xD;
&#xD;
          -  Moderate or severe liver disease defined by specified lab values.&#xD;
&#xD;
          -  Patients who are unable to take oral medication.&#xD;
&#xD;
          -  Life expectancy of &lt; 2 weeks.&#xD;
&#xD;
          -  Any condition that may impair absorption of oral medication.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Coumarin-type anticoagulants.&#xD;
&#xD;
          -  Oral hypoglycemics.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Immunostimulants.&#xD;
&#xD;
          -  Investigational drugs or approved (licensed) drugs for investigational indications&#xD;
             other than aerosolized pentamidine.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Greater than 1 mg/kg/wk amphotericin B.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Summitt Med Ctr / San Francisco Gen Hosp</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

